Medlab Pharmaceuticals

Medlab Clinical is an Australian biotechnology company that specializes in the development of pharmaceutical-grade delivery systems and cannabinoid-based therapeutics. The company's core asset is the NanoCelle platform, a patented delivery technology that creates sub-micron sized particles to enhance the solubility and absorption of medicines via the oral-buccal mucosa. Its lead drug candidate, NanaBis, is a 1:1 THC and CBD formulation designed as an alternative to opioids for managing oncology-related pain. Medlab also maintains a pipeline of programs targeting depression and metabolic health. In 2023, the company's assets and intellectual property were acquired by Hallmark Life Sciences following a period of financial restructuring.